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Glomerular filtration rate (GFR) is an accepted measure for assessment of kidney function. For the critically ill patient, creatinine
clearance is the method of reference for the estimation of the GFR, although this is often not measured but estimated by equations
(i.e., Cockroft-Gault or MDRD) not well suited for the critically ill patient. Functional evaluation of the kidney rests in serum
creatinine (Crs) that is subjected to multiple external factors, especially relevant overhydration and loss of muscle mass. The
laboratory method used introduces variations in Crs, an important fact considering that small increases in Crs have serious
repercussion on the prognosis of patients. Efforts directed to stratify the risk of acute kidney injury (AKI) have crystallized in
the RIFLE or AKIN systems, based in sequential changes in Crs or urine flow. These systems have provided a common definition
of AKI and, due to their sensitivity, have meant a considerable advantage for the clinical practice but, on the other side, have
introduced an uncertainty in clinical research because of potentially overestimating AKI incidence. Another significant drawback
is the unavoidable period of time needed before a patient is classified, and this is perhaps the problem to be overcome in the near
future.
1. Epidemiology of Acute
Kidney Injury in the ICU
Acute kidney injury (AKI) can be defined as a decrease of
the glomerular filtration rate (GFR) that appears acutely,
is maintained for some time, causes an accumulation of
waste products from metabolism and uremic toxins, and
conditions a mishandling of body fluids and a loss of the
ability to maintain homeostasis of electrolytes and acid-base
balance. In the intensive care setting,AKI presentswith a high
incidence and, once established, has an important impact in
the patient and the resources [1, 2].
The reported incidence of AKI in the intensive care units
(ICUs) shows a wide variability depending on the population
analyzed and the criteria employed for its definition, but
when this is based in the new systems for stratification, as
RIFLE [3] or AKIN [4], more than 30% of ICU patients are
found to present with some degree of AKI [5], and mortality
rate increases according to this degree of renal dysfunction
[6, 7]. These figures are a good measure of the magnitude of
the problem, and even when functional recovery after AKI
is good, it has been demonstrated that the development of
severe AKI can lead to an increase in long-termmortality [8]
with an estimation of the incidence of chronic kidney disease
(CKD) after an episode of AKI as high as 7.8 per 100 patients
per year [9, 10].
This scenario has put in evidence the necessity of new
tools for continuous assessment of kidney function given that
the classical approach of measurements of isolated determi-
nations of serum creatinine (Crs) has proven insufficient [11].
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Figure 1: When enough renal mass is present, GFR changes in
response to patient necessities, but when damage is severe this “renal
reserve” is lost. Adapted from [12].
2. Measuring Kidney Function
2.1. Glomerular Filtration Rate. One way to evaluate renal
function is studying its capability to maintain an adequate
rate of filtration in the glomerulus, that is, the GFR.The GFR
is a measure of the amount of blood filtered per unit of time
but not necessarily of kidney damage. We must keep in mind
that a direct relationship between renal mass and changes
in GFR does not exist until late in the process of damage
because the kidneys are able to compensate the loss of renal
mass through a raise in the filtration rate in those nephrons
still functioning (Figure 1) [12]. GFR can be estimated by
the measurement of the rate of elimination (clearance) of
different molecules that are filtered by the glomerulus but
not secreted or reabsorbed by the tubule, and the use of
endogenous molecules naturally producing in the organism
has been proposed for this purpose, mainly Crs.
2.2. Serum Creatinine. Crs is an organic protein resulting
from the degradation of creatine, produced and eliminated at
a constant rate, exclusively cleared by the kidneys, and filtered
at the glomerulus without significant tubular reabsorption
or tubular secretion. Its main drawback is based on the
fact that changes in Crs do not follow a linear relationship
with changes in GFR, so that when detecting changes in
its concentration we must not assume similar changes in
the GFR (Figure 2) [16]. Also, Crs being an endogenous
molecule, its metabolism is subjected to interpersonal vari-
ations depending on different factors [17]. Taking into con-
sideration these aspects, Crs is still the parameter univer-
sally adopted for the diagnosis of kidney failure, but we
must keep in mind that its value reflects the functionality
of the kidney and not necessarily the presence of actual
damage.
Crs is a functional parameter and its role in the diagnosis
of renal injury is closely related to what we can address as
“renal reserve.” When a patient initially presenting a normal
Crs concentration surpasses 2mg/dL, he or she may have lost
approximately 50% of the functioning renal mass [12, 14], but
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Figure 2: Relationship between serum creatinine and creatinine
clearance. Data from the authors, adapted from [13].
on the other hand, changes in Crs after a serious renal insult
depend largely on the basal figures as well, so that 24 hours
after a 90% fall in the creatinine clearance (CrCl), the increase
of Crs might be up to 246% when kidney function is normal
but only 174%when the patient already featured a dysfunction
in stage 2 of the KDIGO guidelines [18] or as low as 74%when
the patient was in stage 4, for a virtually identical absolute
increase in theCrs (between 1.8 and 2mg/dL). For this reason,
some authors have advocated for a definition of AKI based
upon changes of Crs levels for a given period (between 24 and
48 hours) instead of absolute serum levels [19].This approach
palliates the problem derived from the delayed raise in Crs
(more than 48 hours) following a change in GFR (Figure 3)
[14, 15, 18, 19].
2.3. Fluids and Crs. Another key point when assessing serial
changes in Crs is the repercussion of the balance of fluids.
In those situations when aggressive hydration has been
necessary and water balance is positive, the relative serum
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concentration of Crs decreases and therefore underestimates
the real value [20–23].
2.4. Crs Assay. The method described by Jaffe´ for the assay
of Crs has been the cornerstone for the diagnosis of the renal
failure until recently but shows variations for a range from
0.06 to 0.31mg/dL, a range previously considered safe but is
now considered to be of potential prognostic value [24, 25].
This fact has favored its displacement by the enzymatic assay
[26].
2.5. Creatinine Clearance. This method does in effect show
a lineal relationship with GFR and is less affected by the
delayed changes of Crs after GFR decrement but shares all
the other problems of the Crs already mentioned. In routine
ICU clinical practice, CrCl measured with diuresis of 24
hours is not operational, and different investigators have
sought alternatives more adapted to the ICU environment.
An approach is the measurement of CrCl with samples of
urine collected in shorter intervals of time, making repetitive
measures more feasible, urine samples from simultaneous
patients easier to handle, and (the most critical aspect)
without delay for the results [27]. Different timings for
collection of urine have been validated by some authors,
ranging from one hour by Hoste et al. [28], two hours by
Herrera-Gutie´rrez et al. [13] or periods from two to twelve
hours by Wilson and Soullier [29]. In addition, these studies
show how among those patients with Crs in normal or near-
normal range (below 1.5mg/dL) up to 25% already had a
significantly diminished CrCl and also put in evidence that
equations for estimation of GFR in the ICU (Cockroft-Gault
and MDRD) are not adequate [13, 28]. However, despite the
scarcity of studies addressing the validity of these equations
in the acute patient (and specifically in the ICU patient)
and the general agreement against its use in this scenario,
these equations (especially MDRD) have become the usual
tool for estimation of CrCl and guiding prescription of drugs
that require adjustment in the presence of renal dysfunc-
tion [30, 31]. When an exact measure is deemed necessary
none of these equations replaces a measurement of CrCl
[32].
2.6. Cys-C. Cys-C is a low molecular weight protein pro-
duced by all nucleated cells at a constant rate, being filtered
by the glomerulus and reabsorbed and metabolized in the
proximal tubule without tubular secretion and only minimal
extrarenal elimination. Cys-C has shown promising results
as an estimator of GFR in patients with stable renal function
[33, 34].
2.7. Biomarkers of Kidney Injury. Different biomarkers of
kidney injury have recently been evaluated with mixed
results [35]. It is still necessary to define the kinetics of
these molecules and their relationship to the development of
kidney injury [36]. Another important point to emphasize is
that these new biomarkers are not aimed to the assessment of
renal function (do not estimate GFR) and therefore can not
replace but are complementary to Crs or Cys-C.
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Figure 3: Relationship between glomerular filtration rate (GFR) and
serum creatinine (Crs) in time. Adapted from [14, 15].
3. Stratification of AKI
From the moment the aggression occurs until the kidneys
begin to show alterations and dysfunction, different mech-
anisms of compensation have been launched that which
produce a decrease in the GFR [37] but, due to the lack of
sensible methods of diagnosis, we acknowledge the presence
of this renal failure once this initial phase has already been
surpassed. This problem is worsened because there is not a
clear definition of what we must consider AKI [38, 39] but
the definition of two systems aimed to stratify acute kidney
dysfunction based on sequential changes of Crs (RIFLE and
AKIN) has come to fill this gap for the AKI patient (Figure 4)
[3, 4].
The RIFLE (an acronym for risk, injury failure, loss,
and end-stage) system made a proposal for a new definition
considering AKI as a dynamic process. Another major
advantage of this system was its simplicity, advocating for the
use of biomarkers universally affordable (Crs and diuresis).
In 2007, the AKIN (acute kidney injury network) group
designed a new stratification system based on the premises
of the RIFLE system but incorporating the findings from
Lassnigg et al. that demonstrated how small increases in
Crs carry a proportional increase in mortality [24, 40–43].
These two systems have been evaluated in large series of UCI
patients and are currently consolidated as reference, but both
systems present some problems [44] and their introduction
has conditioned a substantial increase in the incidence of AKI
published, having in fact increased on the order of 2 to 10
times [45].
The problem, shared by both systems, is the need for
a minimum timeframe to proceed with the classification,
which in RIFLE extends up to a week and in AKIN for 48
hours. This inevitable time window will condition a delay in
the detection of AKI. Yet another problem with RIFLE arises
from the possibility to choose indistinctly between CrCl or
Crs, evenwhen these values are not linearly related and donot
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Figure 4: RIFLE and AKIN classification systems [3, 4].
change simultaneously in time [46]. Another relevant aspect
and one that questions the consistency of these systems is the
finding of similar outcomes for patients in the AKIN 1 and
2 levels with a significant increment for level 3 and with a
similar behavior for RIFLE [47] that could be suggesting the
convenience for a reappraisal of the ranges of Crs considered
in each level.
4. Conclusion
A proper definition for AKI should establish the presence or
absence of the disease, report on its severity and prognosis,
and, perhaps more important, should be easy to understand
and implement [48]. Although these assumptions have been
partlymet by RIFLE andAKIN, it is likely that in a near future
our understanding aboutAKI and its impactwill bemodified.
It is important to stress the fact that at least 20% of hos-
pitalized patients develop some degree of renal dysfunction,
and the prognosis for these patients worsens as the degree of
dysfunction increases [49] but the fact is that for those who
survive, only 10% will eventually be in need for prolonged
renal replacement [50]. These figures reinforce the relevance
of a timely detection of impending AKI in order to apply
secondary preventive measures and limit its progression,
increasing the chances of recovery of our patients.
Although Crs is a parameter sensible for deciding
whether a patient’s kidney function remains stable, worsens,
or improves, its role in the diagnosis of early renal dysfunc-
tion is more debatable, and in order to evaluate the informa-
tion it provides we must understand the pathophysiology of
acute renal failure and the kinetics of creatinine (be it Crs,
measured CrCl or estimated by equations), and in any case,
we must integrate this information in one of the stratification
systems currently in use, but always acknowledging their
limitations.
Serum creatinine is the key factor in the evaluation
of kidney function because it is affordable, reproducible,
and easy to perform, but clinicians must be aware of its
limitations, among others that it is a functional marker and
not a marker of injury, that changes in Crs are delayed after
changes in GFR, or that fluid changes in critically ill patients
can seriously difficult the capability of Crs to detect small
changes in kidney function.
New trends in stratification (ADQI or AKIN) could have
a significant impact in clinical practice, alerting the clinicians
of the real value of small changes in Crs, and the novel
biomarkers of kidney damage (in particular of tubular injury)
may in the near future have a role in the diagnosis of AKI once
they are included in the classification systems.
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